Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)Christopher J Edwards, Paul Bird, Jeffrey Crowley et al.|Annals of the Rheumatic Diseases|2016Cited by 286